|
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation |
 Follow us on Twitter!
 Join us on Facebook!
Visit us on Navigating Cancer! |
(submitted 5/26/11)
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients.
Read our newest survivor stories:
|
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events! |
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's:
Audited Financial Statements
IRS Form 990
|
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report. |
|
|
|
|
|
|
FDA Approves Sutent for Pancreatic Neuroendocrine Tumors
More exciting news for patients! On May 23, the FDA approved Sutent® (sunitinib malate) for patients with progressive, well-differentiated pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic.
Sutent is the first anti-VEGF FDA-approved therapy for patients with pancreatic neuroendocrine tumors and only the second therapy approved by the FDA to treat pancreatic neuroendocrine tumor patients since 1982. Afinitor received approval on May 6, just weeks before.
Any patients considering this or any other potential treatment should consult with a physician well-versed in treating neuroendocrine tumor patients. Experienced clinicians are necessary to understand the best timing and duration of therapy with Sutent or other potential treatments. Please consult CFCF's Doctor Database or call 617.948.2514 for help finding an experienced clinician. |
|
Join Team CFCF and Make a Difference!
 While there are many worthwhile and well-known fundraising events such as the Relay for Life, it is important to understand that funds raised are unlikely to find their way to carcinoid or related neuroendocrine cancer research. Because carcinoid and related neuroendocrine cancers are rare, they (like other rare cancers) typically fall under the radar and do not garner funding support from organizations like the ACS or the federal government. But there is something you can do! You can create a personalized web page to honor a loved one and raise funds for CFCF. Keep alive the memory of a loved one, celebrate a birthday or anniversary, raise awareness for carcinoid and related neuroendocrine cancers, and support CFCF's life-saving research mission. Click here to see an example of a personalized fundraising page. To get started creating your own unique page, click here. Once you've created your page, share the link with friends and family and you're on your way to making a real difference in the fight to cure carcinoid and related neuroendocrine cancers. If you have questions about setting up a personalized web page, contact us (617.948.2514) and we'll gladly help you get started. |
|
Genomics Research Helps Stimulate Economy
We often discuss how new research studies are vital to improving treatments for patients. But did you know that sponsoring research can also help our economy?
A report from Battelle Memorial Institute, an independent science and technology research and development company, assessed the economic impact of the Human Genome Project and the genomics industry. The report found that after an initial $3.8 billion government investment, genomics research helped drive $796 billion in economic impact and $244 billion in total personal income. In 2010 alone, the genomics industry created 310,000 jobs.
The report states, "Scientists are using the reference genome, the knowledge of genome structure, and the data from the Human Genome Project as the foundation for fundamental advancements in science and medicine and the development of applied genomics tools, techniques and technologies."
CFCF is proud to sponsor cutting-edge genomics research projects such as the Pancreatic Neuroendocrine Tumor Genome Project at Johns Hopkins University and the Carcinoid Cancer Genome Study at Dana-Farber Cancer Institute and the Broad Institute. Read more about these and our other current research projects on our website.
|
|
|
|
|
